1. Fibroblast growth factor 21 inhibits atherosclerosis in apoE-/- mice by ameliorating Fas-mediated apoptosis.
- Author
-
Yan X, Gou Z, Li Y, Wang Y, Zhu J, Xu G, and Zhang Q
- Subjects
- Animals, Apolipoproteins E metabolism, Cytoprotection drug effects, Fibroblast Growth Factors pharmacology, Human Umbilical Vein Endothelial Cells drug effects, Human Umbilical Vein Endothelial Cells metabolism, Humans, Lipoproteins, LDL pharmacology, MAP Kinase Signaling System drug effects, Mice, Inbred C57BL, Mice, Knockout, Apolipoproteins E deficiency, Apoptosis drug effects, Atherosclerosis drug therapy, Atherosclerosis pathology, Fibroblast Growth Factors therapeutic use, fas Receptor metabolism
- Abstract
Background: FGF21 is a critical endogenous regulator in energy homeostasis and systemic glucose and lipid metabolism. Despite intensive study of the metabolic functions of FGF21, its important role in heart disease needs further exploration. Apoptosis induced by ox-LDL in vascular endothelial cells is an important step in the progress of atherosclerosis., Methods: The effects of FGF21 treatment on apoptosis induced by ox-LDL were tested in HUVECs. The role of FGF21 in atherosclerosis was studied by evaluating its function in apolipoprotein E double knockout (apoE-/-) mice., Results: We found that apoptosis in HUVECs was alleviated by FGF21 treatment. The effects of FGF21 were independent of the ERK1/2 pathway and were mediated through inhibition of the Fas signaling pathway. FGF21 suppressed the development of atherosclerosis, and the administration of FGF21 ameliorated Fas-mediated apoptosis in apoE-/- mice., Conclusion: FGF21 protects against apoptosis in HUVECs by suppressing the expression of Fas; furthermore, FGF21 alleviated atherosclerosis by ameliorating Fas-mediated apoptosis in apoE-/- mice.
- Published
- 2018
- Full Text
- View/download PDF